deferasiroks pliva 500 mg/1 tableta tableta za oralnu suspenziju
pliva d.o.o.sarajevo - deferasiroks - tableta za oralnu suspenziju - 500 mg/1 tableta - 1 tableta za oralnu suspenziju sadrži: 500 mg deferasiroksa
fuarte (▼) 500 mg/1 tableta tableta za oralnu suspenziju
abdi ibrahim bh d.o.o. sarajevo - deferasiroks - tableta za oralnu suspenziju - 500 mg/1 tableta - 1 tableta za oralnu suspenziju sadrži: 500mg deferasiroksa
fuarte (▼) 125 mg/1 tableta tableta za oralnu suspenziju
abdi ibrahim bh d.o.o. sarajevo - deferasiroks - tableta za oralnu suspenziju - 125 mg/1 tableta - 1 tableta za oralnu suspenziju sadrži: 125 mg deferasiroksa
fuarte (▼) 250 mg/1 tableta tableta za oralnu suspenziju
abdi ibrahim bh d.o.o. sarajevo - deferasiroks - tableta za oralnu suspenziju - 250 mg/1 tableta - 1 tableta za oralnu suspenziju sadrži: 250mg deferasiroksa
demyral 500 mg/1 tableta tableta za oralnu suspenziju
tuzlafarm d.o.o. tuzla - deferasiroks - tableta za oralnu suspenziju - 500 mg/1 tableta - 1 tableta za oralnu suspenziju sadrži: 500 mg deferasiroksa
demyral 250 mg/1 tableta tableta za oralnu suspenziju
tuzlafarm d.o.o. tuzla - deferasiroks - tableta za oralnu suspenziju - 250 mg/1 tableta - 1 tableta za oralnu suspenziju sadrži: 250 mg deferasiroksa
demyral 125 mg/1 tableta tableta za oralnu suspenziju
tuzlafarm d.o.o. tuzla - deferasiroks - tableta za oralnu suspenziju - 125 mg/1 tableta - 1 tableta za oralnu suspenziju sadrži: 125mg deferasiroksa
fingolimod mylan
mylan ireland limited - финголимод hidroklorid - multipla skleroza, Рецидивно-Ремиттирующее - imunosupresivi - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older:patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 i 5. 1)orpatients s brzo razvija težak relapsing ublažavanje multiplom sklerozom određuje se 2 ili više teških recidiva u roku od jedne godine, s 1 ili više gadolinij revitalizacije lezija na mr mozga ili značajno povećanje opterećenja t2 lezija u odnosu na najnoviji mri.
fingolimod mylan
mylan ireland limited - финголимод hidroklorid - multipla skleroza, Рецидивно-Ремиттирующее - imunosupresivi - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 i 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.
multihance 0,5 mmol/1 ml otopina za injekciju
mark medical d.o.o. sarajevo - gadobenat - otopina za injekciju - 0,5 mmol/1 ml - 1 ml otopine za injekciju sadrži: 529 mg (334 mg (0,5 mmol) + 195 mg) gadobenat dimeglumina (gadobenična kiselina + meglumin)